Munus ranks 14+ competing biologics for each IBD patient using integrated immune-pathway phenotype, prior drug-response history, and exposure signature. Precision biologic intelligence for autoimmune medicine.
Phase 3 trials show 30–45% clinical remission on first-line biologics[1] — the majority of patients cycle drugs before finding what works. Each failed prescription costs the payer $30–50K and the patient 6–12 months of active disease per drug cycled.[2] Pharma loses brand share to competitors at every non-responder switch. No commercial decision-support tool exists for biologic selection in autoimmune medicine.
Munus integrates immune-pathway phenotype (Th1, Th17, NF-κB, NLRP3), prior drug-response history, exposure signature, and symptom pattern into a multi-modal inference model. Output: ranked biologic candidates with mechanism-aligned rationale, exported as a prior-auth-ready clinical brief. Decision support, not diagnosis.
Drop patient files (PDF, DOCX, DICOM). Munus de-identifies automatically and extracts structured findings from unstructured records.
Algorithm produces a ranked list of biologic candidates with mechanism-aligned rationale. Top match plus alternatives, each with supporting clinical reasoning.
Export the prior-auth-ready clinical brief with rationale, dosing, and payer documentation. Direct to EMR or share with the patient.
Three precision-medicine platforms in oncology have validated the model. Same three-channel non-exclusive structure Munus runs in autoimmune.
Tempus and Foundation own oncology. Recursion and Insitro own drug discovery. No incumbent owns autoimmune + point-of-care. That's the Munus quadrant — and it's a $30–40B market.
Most precision medicine is genomic only. Munus integrates pathway phenotype, prior drug-response history, exposure signature, and symptom pattern into a single inference layer that no genomic-only competitor can match.
Same algorithm packaged for clinicians ($1,200/test, billable via existing decision-support codes), pharma (target BD partnerships $5–50M, non-exclusive), and payers (target enterprise contracts $0.1–10M/yr). The Tempus playbook applied to autoimmune.
The Gut Health Solution clinic is Munus's first customer. Real cases generate the real-world outcomes data flywheel that pharma and payers will pay to access in Phase 2 and Phase 3.
Munus is raising a seed round. We're open to investor conversations, clinical pilot partnerships, and KOL advisor introductions.